Fujifilm Enters Growing Market of Vaccine Contract Manufacturing
Fujifilm Corporation has announced an agreement to acquire Kalon Biotherapeutics, a biopharmaceutical CMO having expertise in vaccine manufacturing, and will enter the vaccine CMO market to expand its biopharmaceutical business.
On 22 October 2014, Fujifilm Diosynth Biotechnologies — a Fujifilm subsidiary — signed an Interest Purchase Agreement, with the owners of Kalon. At the initial closing of this transaction expected to occur within the next few months, FDBU will acquire 49% of the total membership interests in Kalon and will be entitled to appoint a majority of Kalon’s board members. Thereafter, FDBU may increase its interest share up to 100% based on achievement of certain milestones set forth in the Interest Purchase Agreement.
Kalon is a biopharmaceutical CMO with advanced technologies and facilities and is a key subcontractor to one of the three Centers For Innovation In Advanced Development and Manufacturing (CIADM) awarded by the US Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) to develop and manufacture medical countermeasures to protect public health in emergencies, including incidents of bioterrorism or an outbreak of pandemic influenza. The state of Texas, through the Texas Emerging Technology Fund, provided funding critical to the development and support of this center.
Kalon’s strength is in manufacturing vaccines using the technique of mammalian cell culture. It employs world class technologies for robust, high containment manufacturing, which completely contains the viruses used to manufacture vaccines inside production suites, thereby enabling safe, stable manufacture of vaccines to be used as public medical countermeasures against threats such as pandemic influenza, Ebola and Anthrax. In addition, Kalon utilises state-of-the-art mobile clean rooms (MCRs) featuring high containment, compactness and mobility. Up to twenty MCRs can be installed at the National Center for Therapeutics Manufacturing facility operated by Kalon. The MCRs enable concurrent manufacturing of several types of vaccines. Moreover, the ability to easily expand the number of MCRs allows for prompt response to increasing capacity demands.
These MCRs are suitable not only for cell-cultured vaccines, but also for all kinds of biopharmaceuticals, including antibodies, and meet the growing demand for high-variety low-volume manufacturing.
Fujifilm entered biopharmaceutical CMO business by acquiring FDBU and Fujifilm Diosynth Biotechnologies UK Limited from Merck & Co., Inc in 2011 and has been expanding its businesses through the partnership with Mitsubishi Corporation, who has extensive experiences in the pharmaceutical business.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance